NCT03592264 - A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

February 13, 2024

Study Completion Date

March 21, 2024

Conditions

Solid TumorPancreatic Adenocarcinoma

Interventions

DRUG

OBI-3424

liquid formulation for Intravenous infusion

Trial Locations (5)

Ohio State University Comprehensive Cancer Center, Columbus

MD Anderson Cancer Center, Houston

USC Norris Comprehensive Cancer Center, Los Angeles

Scripps Clinic Torrey Pines, La Jolla

Rutgers Cancer Institute of New Jersey, New Brunswick